250 related articles for article (PubMed ID: 36906109)
1. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide profiling of transcription factor activity in primary liver cancer using single-cell ATAC sequencing.
Craig AJ; Silveira MAD; Ma L; Revsine M; Wang L; Heinrich S; Rae Z; Ruchinskas A; Dadkhah K; Do W; Behrens S; Mehrabadi FR; Dominguez DA; Forgues M; Budhu A; Chaisaingmongkol J; Hernandez JM; Davis JL; Tran B; Marquardt JU; Ruchirawat M; Kelly M; Greten TF; Wang XW
Cell Rep; 2023 Nov; 42(11):113446. PubMed ID: 37980571
[TBL] [Abstract][Full Text] [Related]
3.
Hill MA; Alexander WB; Guo B; Kato Y; Patra K; O'Dell MR; McCall MN; Whitney-Miller CL; Bardeesy N; Hezel AF
Cancer Res; 2018 Aug; 78(16):4445-4451. PubMed ID: 29871934
[TBL] [Abstract][Full Text] [Related]
4. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
5. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
Sia D; Villanueva A; Friedman SL; Llovet JM
Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
[TBL] [Abstract][Full Text] [Related]
6. Necroptosis microenvironment directs lineage commitment in liver cancer.
Seehawer M; Heinzmann F; D'Artista L; Harbig J; Roux PF; Hoenicke L; Dang H; Klotz S; Robinson L; Doré G; Rozenblum N; Kang TW; Chawla R; Buch T; Vucur M; Roth M; Zuber J; Luedde T; Sipos B; Longerich T; Heikenwälder M; Wang XW; Bischof O; Zender L
Nature; 2018 Oct; 562(7725):69-75. PubMed ID: 30209397
[TBL] [Abstract][Full Text] [Related]
7. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
8. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
[TBL] [Abstract][Full Text] [Related]
9. Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Pomyen Y; Chaisaingmongkol J; Rabibhadana S; Pupacdi B; Sripan D; Chornkrathok C; Budhu A; Budhisawasdi V; Lertprasertsuke N; Chotirosniramit A; Pairojkul C; Auewarakul CU; Ungtrakul T; Sricharunrat T; Phornphutkul K; Sangrajang S; Loffredo CA; Harris CC; Mahidol C; Wang XW; Ruchirawat M;
Sci Rep; 2023 Jul; 13(1):11406. PubMed ID: 37452065
[TBL] [Abstract][Full Text] [Related]
10. Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma.
Jeon Y; Kwon SM; Rhee H; Yoo JE; Chung T; Woo HG; Park YN
Hepatology; 2023 Jan; 77(1):92-108. PubMed ID: 35124821
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
[TBL] [Abstract][Full Text] [Related]
12. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
[TBL] [Abstract][Full Text] [Related]
13. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA.
Sakano Y; Noda T; Kobayashi S; Kitagawa A; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Asaoka T; Tanemura M; Umeshita K; Mimori K; Doki Y; Eguchi H
Dig Dis Sci; 2022 Aug; 67(8):3817-3830. PubMed ID: 34626299
[TBL] [Abstract][Full Text] [Related]
15. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
[TBL] [Abstract][Full Text] [Related]
16. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
[TBL] [Abstract][Full Text] [Related]
18. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression.
Di-Luoffo M; Pirenne S; Saandi T; Loriot A; Gérard C; Dauguet N; Manzano-Núñez F; Alves Souza Carvalhais N; Lamoline F; Cordi S; Konobrocka K; De Greef V; Komuta M; Halder G; Jacquemin P; Lemaigre FP
Hepatology; 2021 Sep; 74(3):1445-1460. PubMed ID: 33768568
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
20. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.
Nguyen Canh H; Takahashi K; Yamamura M; Li Z; Sato Y; Yoshimura K; Kozaka K; Tanaka M; Nakanuma Y; Harada K
Histopathology; 2021 Nov; 79(5):731-750. PubMed ID: 34018212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
